Trevena Inc. had a painful end to 2018 with the FDA's Anesthetic and Analgesic Drug Products Advisory Committee voting 7-8 against recommending the proposed 0.1-mg and 0.35-mg doses of oliceridine, followed by a complete response letter (CRL) from the FDA the subsequent month.